The GLP-1 Lab Panel: Which Blood Tests Your Doctor Should Order and When

Laboratory monitoring is one of the most important — and most inconsistently practiced — aspects of GLP-1 treatment. Some providers order comprehensive baseline panels and regular follow-ups. Others prescribe without any lab work at all. Understanding which tests matter and why helps you advocate for proper clinical oversight of your treatment.

Before Starting: The Baseline Panel

Every patient should have the following lab work completed before their first GLP-1 dose. These tests establish your metabolic starting point and screen for conditions that may affect prescribing decisions:

Essential Baseline Labs

• Comprehensive Metabolic Panel (CMP) — includes glucose, kidney function markers (BUN, creatinine, eGFR), liver enzymes (AST, ALT), and electrolytes. This single panel covers multiple safety checkpoints.
• Hemoglobin A1C — measures average blood sugar over the past 2-3 months. Critical for identifying undiagnosed diabetes or prediabetes, which affects medication choice and monitoring cadence.
• Lipid Panel — total cholesterol, LDL, HDL, triglycerides. Establishes cardiovascular risk baseline and provides a benchmark to measure improvement (GLP-1 medications often significantly improve lipid profiles).
• Thyroid Function (TSH) — screens for hypothyroidism (which can impair weight loss response) and establishes baseline for monitoring the thyroid safety profile.

Recommended Additional Baseline Labs

• Complete Blood Count (CBC) — identifies anemia, which could worsen with rapid weight loss and caloric restriction
• Amylase and Lipase — pancreatic enzyme baseline. If pancreatitis symptoms develop during treatment, having baseline values is clinically invaluable for comparison.
• Vitamin D, B12, and Iron studies — nutritional deficiencies are common in patients with obesity and can worsen during GLP-1 treatment due to reduced food intake
• Uric acid — rapid weight loss can trigger gout flares in susceptible patients; baseline uric acid helps predict this risk

During Treatment: Monitoring Schedule

The frequency and scope of monitoring labs during GLP-1 treatment depends on your individual risk factors and how treatment is progressing. Here's a general framework that aligns with current clinical best practices:

Month 3 (First Follow-Up Panel)

By month 3, you should be at or approaching therapeutic doses. This is an ideal time to check:

• CMP (kidney and liver function, glucose) — to ensure no adverse metabolic changes
• A1C — particularly if baseline was elevated; you should see improvement
• Lipid panel — early changes in lipid profile may be apparent

Month 6 (Mid-Treatment Assessment)

At 6 months, most patients are experiencing significant weight loss. This is the point where nutritional monitoring becomes important:

• CMP, A1C, lipid panel (continue monitoring)
• CBC — check for developing anemia
• Vitamin D, B12, iron — check for nutritional deficiencies emerging from reduced caloric intake
• TSH — recheck thyroid function, especially if on levothyroxine

Annual Monitoring

For patients on long-term GLP-1 therapy, annual comprehensive lab work should include all of the above plus any condition-specific monitoring (e.g., retinal exams for diabetic patients, bone density for postmenopausal women experiencing rapid weight loss).

Special Monitoring Situations

Patients with Type 2 Diabetes: If you're on insulin or sulfonylureas alongside a GLP-1, glucose monitoring should be more frequent — daily fingerstick or continuous glucose monitoring (CGM) — especially during GLP-1 titration when hypoglycemia risk is highest.

Patients with Kidney Disease: GLP-1 medications are generally considered renal-safe and may even be nephroprotective. However, the dehydration risk from GI side effects (vomiting, diarrhea) can acutely impair kidney function in patients with pre-existing kidney disease. More frequent creatinine and eGFR monitoring (every 1-2 months initially) is warranted.

Patients on Warfarin: INR should be monitored weekly during GLP-1 initiation and at each dose increase, then monthly once stable.

Understanding Your Lab Results in Context

As you lose weight on GLP-1 medications, some lab values will change in ways that might seem concerning but are actually expected and benign:

• Liver enzymes (AST, ALT) may temporarily increase during rapid weight loss as fat is mobilized from the liver. Mild elevations (up to 2x upper limit of normal) that trend downward are not alarming.
• Uric acid may spike during rapid weight loss, occasionally triggering gout. If you have a history of gout, prophylactic colchicine may be discussed with your provider.
• Electrolytes — sodium, potassium, and magnesium can shift with reduced food intake and increased water consumption. Stay consistent with hydration and don't over-restrict salt intake.